Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review (Q37804381)

23 August 2017

title

Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review (English)

1 reference

juvenile rheumatoid arthritis

23 August 2017

main subject

1 reference

Susan Shenoi

1

1 reference

23 August 2017

Carol A Wallace

series ordinal

2

1 reference

23 August 2017

publication date

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

12

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

367-377

1 reference

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

23 August 2017

cites work

1 reference

12 December 2020

Evaluation of tumour necrosis factor alpha, interferon gamma and granulocyte-macrophage colony stimulating factor levels in juvenile chronic arthritis

1 reference

12 December 2020

Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers.

1 reference

12 December 2020

Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period

1 reference

12 December 2020

Adalimumab in juvenile rheumatoid arthritis

1 reference

12 December 2020

Infliximab in two patients with juvenile ankylosing spondylitis

1 reference

12 December 2020

Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies.

1 reference

12 December 2020

Etanercept in systemic juvenile idiopathic arthritis

1 reference

12 December 2020

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

1 reference

12 December 2020

Preliminary definition of improvement in juvenile arthritis

1 reference

12 December 2020

Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents

1 reference

12 December 2020

Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.

1 reference

12 December 2020

Long-term outcome of etanercept therapy in children with treatment-refractory uveitis

1 reference

12 December 2020

Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.

1 reference

12 December 2020

DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition

1 reference

12 December 2020

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

1 reference

12 December 2020

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

1 reference

12 December 2020

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

1 reference

12 December 2020

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

12 December 2020

Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study

1 reference

12 December 2020

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

1 reference

12 December 2020

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

1 reference

12 December 2020

Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis

1 reference

12 December 2020

TNF pathophysiology in murine models of chronic inflammation and autoimmunity.

1 reference

12 December 2020

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

1 reference

12 December 2020

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

1 reference

12 December 2020

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

12 December 2020

Adalimumab therapy for childhood uveitis

1 reference

12 December 2020

Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis

1 reference

12 December 2020

Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis

1 reference

12 December 2020

Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis

1 reference

12 December 2020

Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis

1 reference

12 December 2020

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

1 reference

12 December 2020

A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis

1 reference

12 December 2020

Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children

1 reference

12 December 2020

Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis

1 reference

12 December 2020

Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis

1 reference

12 December 2020

Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.

1 reference

12 December 2020

Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study

1 reference

12 December 2020

Soluble tumor necrosis factor receptors in human inflammatory synovial fluids

1 reference

12 December 2020

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

1 reference

12 December 2020

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

1 reference

12 December 2020

Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

1 reference

12 December 2020

Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis

1 reference

12 December 2020

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

1 reference

12 December 2020

Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel thesitis with adalimumab documented by magnetic resonance imaging

1 reference

12 December 2020

Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.

1 reference

12 December 2020

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

1 reference

12 December 2020

A case of childhood-onset ankylosing spondylitis: diagnosis and treatment

1 reference

12 December 2020

Adalimumab in the therapy of uveitis in childhood

1 reference

12 December 2020

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

1 reference

12 December 2020

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis

1 reference

12 December 2020

Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis

1 reference

12 December 2020

Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis

1 reference

12 December 2020

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

12 December 2020

Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis.

1 reference

12 December 2020

TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritides

1 reference

12 December 2020

Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis

1 reference

12 December 2020

Rheumatoid arthritis and its animal models: the role of TNF-alpha and the possible absence of specific immune reactions

1 reference

12 December 2020

Summary of worldwide pediatric malignancies reported after exposure to etanercept

1 reference

12 December 2020

Tumor necrosis factor blockade in the management of children with orphan diseases.

1 reference

12 December 2020

Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy

1 reference

12 December 2020

Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years

1 reference

12 December 2020

Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy.

1 reference

12 December 2020

A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study

1 reference

12 December 2020

The tumor necrosis factor ligand and receptor families.

1 reference

12 December 2020

Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis.

1 reference

12 December 2020

Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis

1 reference

12 December 2020

The German etanercept registry for treatment of juvenile idiopathic arthritis

1 reference

12 December 2020

Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes

1 reference

12 December 2020

The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized 'anti-TNF' therapies

1 reference

12 December 2020

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

12 December 2020

Etanercept therapy in children with treatment-resistant uveitis

1 reference

12 December 2020

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis

1 reference

12 December 2020

Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis.

1 reference

12 December 2020

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

1 reference

12 December 2020

Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.

1 reference

12 December 2020

Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2).

1 reference

12 December 2020

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis

1 reference

12 December 2020

Etanercept and uveitis in patients with juvenile idiopathic arthritis.

1 reference

12 December 2020

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

12 December 2020

Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration

1 reference

12 December 2020

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

1 reference

12 December 2020

Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity

1 reference

12 December 2020

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

12 December 2020

Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis

1 reference

12 December 2020

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

1 reference

12 December 2020

Infliximab for juvenile idiopathic arthritis-associated uveitis

1 reference

12 December 2020

Prolonged efficacy of etanercept in refractory enthesitis-related arthritis

1 reference

12 December 2020

Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis

1 reference

12 December 2020

Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation

1 reference

12 December 2020

The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor

1 reference

12 December 2020

Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy

1 reference

12 December 2020

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

1 reference

12 December 2020

Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study

1 reference

12 December 2020

Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?

1 reference

12 December 2020

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

12 December 2020

Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.

1 reference

12 December 2020

Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients

1 reference

12 December 2020

Retrospective case review of pediatric patients with uveitis treated with infliximab

1 reference

12 December 2020

Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis

1 reference

12 December 2020

Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis

1 reference

12 December 2020

Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis

1 reference

12 December 2020

Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis

1 reference

12 December 2020

Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis

1 reference

12 December 2020

Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound

1 reference

12 December 2020

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis

1 reference

12 December 2020

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

1 reference

12 December 2020

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

1 reference

12 December 2020

10.2165/11532610-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1009578111

0 references

1 reference